Evidence map›Paper›PMID 30111323›Full record

ArticleMolecular cancer2018

Exosomes derived from mesenchymal stem cells enhance radiotherapy-induced cell death in tumor and metastatic tumor foci.

Virgínea de Araujo Farias, Francisco O'Valle, Santiago Serrano-Saenz, Per Anderson, Eduardo Andrés, Jesús López-Peñalver, Isabel Tovar, Ana Nieto, Ana Santos, Francisco Martín and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Extracellular vesicles role in radio(nuclide)therapy.Journal of radiation research · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Virgínea de Araujo FariasInstituto Universitario de Investigación en Biopatología y Medicina Regenerativa, Centro de Investigación Biomédica, PTS Granada and CIBERONC (Instituto de Salud Carlos III), 18016, Granada, Spain.
Francisco O'ValleInstituto Universitario de Investigación en Biopatología y Medicina Regenerativa, Centro de Investigación Biomédica, PTS Granada and CIBERONC (Instituto de Salud Carlos III), 18016, Granada, Spain.
Santiago Serrano-SaenzInstituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas, PTS Granada, 18016 and CIBERONC (Instituto de Salud Carlos III), Granada, Spain.
Per AndersonGENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, PTS Granada, 18016, Granada, Spain.
Eduardo AndrésInstituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas, PTS Granada, 18016 and CIBERONC (Instituto de Salud Carlos III), Granada, Spain.
Jesús López-PeñalverInstituto Universitario de Investigación en Biopatología y Medicina Regenerativa, Centro de Investigación Biomédica, PTS Granada and CIBERONC (Instituto de Salud Carlos III), 18016, Granada, Spain.
Isabel TovarComplejo Hospitalario de Granada, Servicio Andaluz de Salud, PTS Granada, 18016, Granada, Spain.
Ana NietoInstituto Universitario de Investigación en Biopatología y Medicina Regenerativa, Centro de Investigación Biomédica, PTS Granada and CIBERONC (Instituto de Salud Carlos III), 18016, Granada, Spain.
Ana SantosInstituto Universitario de Investigación en Biopatología y Medicina Regenerativa, Centro de Investigación Biomédica, PTS Granada and CIBERONC (Instituto de Salud Carlos III), 18016, Granada, Spain.
Francisco MartínGENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, PTS Granada, 18016, Granada, Spain.
José ExpósitoComplejo Hospitalario de Granada, Servicio Andaluz de Salud, PTS Granada, 18016, Granada, Spain.
F Javier OliverInstituto de Parasitología y Biomedicina "López Neyra", Consejo Superior de Investigaciones Científicas, PTS Granada, 18016 and CIBERONC (Instituto de Salud Carlos III), Granada, Spain. joliver@ipb.csic.es.
José Mariano Ruiz de AlmodóvarInstituto Universitario de Investigación en Biopatología y Medicina Regenerativa, Centro de Investigación Biomédica, PTS Granada and CIBERONC (Instituto de Salud Carlos III), 18016, Granada, Spain. jmrdar@ugr.es.
Complejo Hospitalario Universitario de Granada · ESCentro de Investigación Biomédica en Red de Cáncer · ESPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESUniversidad de Granada · ESConsejo Superior de Investigaciones Científicas · ESInstituto de Parasitología y Biomedicina "López - Neyra" · ESInstituto de Salud Carlos III · ESParque Tecnológico de la Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe have recently shown that radiotherapy may not only be a successful local and regional treatment but, when combined with MSCs, may also be a novel systemic cancer therapy. This study aimed to investigate the role of exosomes derived from irradiated MSCs in the delay of tumor growth and metastasis after treatment with MSC + radiotherapy (RT).

methodsWe have measured tumor growth and metastasis formation, of subcutaneous human melanoma A375 xenografts on NOD/SCID-gamma mice, and the response of tumors to treatment with radiotherapy (2 Gy), mesenchymal cells (MSC), mesenchymal cells plus radiotherapy, and without any treatment. Using proteomic analysis, we studied the cargo of the exosomes released by the MSC treated with 2 Gy, compared with the cargo of exosomes released by MSC without treatment.

resultsThe tumor cell loss rates found after treatment with the combination of MSC and RT and for exclusive RT, were: 44.4% % and 12,1%, respectively. Concomitant and adjuvant use of RT and MSC, increased the mice surviving time 22,5% in this group, with regard to the group of mice treated with exclusive RT and in a 45,3% respect control group. Moreover, the number of metastatic foci found in the internal organs of the mice treated with MSC + RT was 60% less than the mice group treated with RT alone. We reasoned that the exosome secreted by the MSC, could be implicated in tumor growth delay and metastasis control after treatment.

conclusionsOur results show that exosomes derived form MSCs, combined with radiotherapy, are determinant in the enhancement of radiation effects observed in the control of metastatic spread of melanoma cells and suggest that exosome-derived factors could be involved in the bystander, and abscopal effects found after treatment of the tumors with RT plus MSC. Radiotherapy itself may not be systemic, although it might contribute to a systemic effect when used in combination with mesenchymal stem cells owing the ability of irradiated MSCs-derived exosomes to increase the control of tumor growth and metastasis.

Indexed as

AnimalsCell Line, TumorCell ProliferationCombined Modality TherapyExosomesHumansMCF-7 CellsMelanomaMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMice, Inbred NODMice, SCIDNeoplasm MetastasisProteomicsRadiotherapyTreatment OutcomeAbscopal effectAnnexin A1Bystander effectCell therapyExperimental radiotherapyMelanoma xenograftMesenchymal stem cellsMetastasis spreadProteomic analysis

Identifiers

PMID30111323
PMCPMC6094906
OpenAlexW2886823104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.